MedTrace Logo

Study of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC)

NCT01574430 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 131

Last updated 2016-08-16

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and efficacy of PDT at 30% verteporfin dose in the treatment of CSC.

Conditions

  • Central Serous Chorioretinopathy

Interventions

PROCEDURE

PDT

30% or 50% verteporfin dose PDT was given to patients with CSC

Sponsors & Collaborators

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Mingwei Zhao, M.D · Peking University People's Hospital

  • Youxin Chen, M.D · Peking Union Medical College

  • Feng Zhang, M.D · Beijing Tongren Hospital of Capital Medical University

  • Hong Dai, M.D · Beijing Hospital

  • Xiaoxin Li, M.D · Peking University People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2012-12-31
Completion
2014-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01574430 on ClinicalTrials.gov